297 related articles for article (PubMed ID: 32185708)
1. Mechanisms of Resistance to Checkpoint Blockade Therapy.
Shi H; Lan J; Yang J
Adv Exp Med Biol; 2020; 1248():83-117. PubMed ID: 32185708
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
3. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
4. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
8. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Shergold AL; Millar R; Nibbs RJB
Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
[TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
11. Understanding genetic determinants of resistance to immune checkpoint blockers.
Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
[TBL] [Abstract][Full Text] [Related]
12. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
13. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.
Bellone M; Elia AR
Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Development of Immune Checkpoint Inhibitors.
Wang J; Yang T; Xu J
Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
[TBL] [Abstract][Full Text] [Related]
15. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
17. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
20. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS
Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]